• 1
    Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 7174; discussion 74–5
  • 2
    Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199202; discussion 202–3
  • 3
    Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163166; discussion 166–7
  • 4
    Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159: 12471250
  • 5
    Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152157
  • 6
    Noguchi M, Matsuoka K, Koga H, Kanetake H, Nakagawa M, Naito S. A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan. Int J Clin Oncol 2006; 11: 390395
  • 7
    Shandera KC, Thibault GP, Deshon GE. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998; 52: 644646
  • 8
    Galfano A, Novara G, Iafrate M et al. Prostate Biopsy: the Transperineal Approach. EAU-EBU Update Series 2007; 5: 241249
  • 9
    Stevens MJ, Stricker PD, Saalfeld J et al. Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation: initial Australian experience. Australas Radiol 2003; 47: 152160
  • 10
    USANZ. Prostate Biopsy Audit Report. Edgecliff: Urological Society of Australia and New Zealand, 2005
  • 11
    USANZ. Prostate Biopsy Audit Report. Edgecliff: Urological Society of Australia and New Zealand, 2007
  • 12
    Emiliozzi P, Scarpone P, DePaula F et al. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004; 171: 197199
  • 13
    Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH. Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. Urology 2000; 56: 617621
  • 14
    Demura T, Hioka T, Furuno T et al. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. Cancer 2005; 103: 18261832
  • 15
    Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T, Kageyama Y. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol 2004; 11: 613618
  • 16
    Furuno T, Demura T, Kaneta T et al. Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 2004; 58: 7681
  • 17
    Satoh T, Matsumoto K, Fujita T et al. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005; 66: 114118
  • 18
    Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Prostate cancer detection: relationship to prostate size. Urology 1999; 53: 764768
  • 19
    Raaijmakers R, Kirkels W, Roobol M, Wildhagen M, Schrder F. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826830
  • 20
    Berger AP, Gozzi C, Steiner H et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004; 171: 14781480; discussion 1480–1
  • 21
    Kawakami S, Yamamoto S, Numao N, Ishikawa Y, Kihara K, Fukui I. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol 2007; 14: 719724
  • 22
    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205213
  • 23
    Yuasa T, Tsuchiya N, Kumazawa T et al. Characterization of prostate cancer detected at repeat biopsy. BMC Urol 2008; 8: 14
  • 24
    Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004; 172: 9497
  • 25
    Taira AV, Merrick GS, Galbreath RW et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010; 13: 7177
  • 26
    Thompson IM, Leach RJ, Ankerst DP. Prostate Cancer Detection: a View of the Future. Eur Urol 2011; 59: 191193
  • 27
    Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy–are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952955; discussion 955
  • 28
    Kim SJ, Kim SI, Ahn HS, Choi JB, Kim YS, Kim SJ. Risk factors for acute prostatitis after transrectal biopsy of the prostate. Korean J Urol 2010; 51: 426430
  • 29
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126131
  • 30
    Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008; 15: 457459
  • 31
    Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009; 74: 332338
  • 32
    Cullen IM, Manecksha RP, McCullagh E et al. The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999–2009. BJU Int 2012; 109: 11981206
  • 33
    Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657686
  • 34
    Cannon GM, Smaldone MC, Paterson DL. Extended-spectrum beta-lactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis. Can J Urol 2007; 14: 36533655
  • 35
    Duplessis CA, Bavaro M, Simons MP et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79: 556561
  • 36
    Merrick GS, Gutman S, Andreini H et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007; 52: 715723
  • 37
    Brawer MK. The Influence of Prostate Volume on Prostate Cancer Detection. Eur Urol Suppl 2002; 11: 3539
  • 38
    Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores – is it necessary? Urol Int 2005; 74: 1922
  • 39
    Ficarra V, Novella G, Novara G et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol 2005; 48: 932937
  • 40
    Cohen RJ, Shannon BA, Phillips M, Moorin RE, Wheeler TM, Garrett KL. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol 2008; 179: 17621767
  • 41
    Shannon BA, Mc Neal JE, Cohen RJ. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 2003; 35: 467471
  • 42
    McNeal JE, Bostwick DG. Anatomy of the Prostate: Implication for Disease. New York: Churchill-Livingstone, 1990
  • 43
    Emiliozzi P, Corsetti A, Tassi B, Federico G, Martini M, Pansadoro V. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 2003; 61: 961966
  • 44
    Kawakami S, Hyochi N, Yonese J et al. Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol 2006; 11: 127132
  • 45
    Watanabe M, Hayashi T, Tsushima T, Irie S, Kaneshige T, Kumon H. Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection. Int J Urol 2005; 12: 959963
  • 46
    Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology 2007; 70: 2735